{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:48:23Z","timestamp":1762177703462,"version":"3.40.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12010-024-05112-0","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T08:37:39Z","timestamp":1732783059000},"page":"1773-1789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway"],"prefix":"10.1007","volume":"197","author":[{"given":"Yuepeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"5112_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021). Cholangiocarcinoma. Nat Rev Dis Primers., 7, 65.","journal-title":"Cholangiocarcinoma. Nat Rev Dis Primers."},{"key":"5112_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","volume":"8","author":"B Blechacz","year":"2011","unstructured":"Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011). Clinical diagnosis and staging of cholangiocarcinoma. Nature Reviews. Gastroenterology & Hepatology, 8, 512\u2013522.","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"5112_CR3","doi-asserted-by":"crossref","unstructured":"Miyabe K, Chandrasekhara V, Wongjarupong N, Chen J, Yang L, Johnson S, Chia N, Walther-Antonio M, Yao JZ, Harrington SC, Nordyke CK, Eaton JE, Gossard AA, Oli S, Ali HA, Lavu S, Giama NH, Hassan FA, Ali HM, Enders FT, Ilyas SI, Gores GJ, Topazian MD, Kashyap PC and Roberts LR. Potential role of inflammation-promoting biliary microbiome in primary sclerosing cholangitis and cholangiocarcinoma. Cancers (Basel). 2022; 14: .","DOI":"10.3390\/cancers14092120"},{"key":"5112_CR4","first-page":"95","volume":"32","author":"DA Schwartz","year":"1980","unstructured":"Schwartz, D. A. (1980). Helminths in the induction of cancer: Opisthorchis viverrini, Clonorchis sinensis and cholangiocarcinoma. Tropical and geographical medicine., 32, 95.","journal-title":"Tropical and geographical medicine."},{"key":"5112_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2020). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Journal of Hepatology, 72, 95\u2013103.","journal-title":"Journal of Hepatology"},{"key":"5112_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil, M., & Khan, S. A. (2022). Current epidemiology of cholangiocarcinoma in Western countries. Journal of Hepatology, 77, 1690\u20131698.","journal-title":"Journal of Hepatology"},{"key":"5112_CR7","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12\u201349.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"5112_CR8","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2023). Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA: A Cancer Journal for Clinicians, 73, 198\u2013222.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"5112_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40495-022-00282-z","volume":"8","author":"K Harini","year":"2022","unstructured":"Harini, K., Pallavi, P., Gowtham, P., Girigoswami, K., & Girigoswami, A. (2022). Smart polymer-based reduction responsive therapeutic delivery to cancer cells. Current pharmacology reports., 8, 205\u2013211.","journal-title":"Current pharmacology reports."},{"key":"5112_CR10","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1016\/j.xphs.2023.08.014","volume":"112","author":"MK Shurfa","year":"2023","unstructured":"Shurfa, M. K., Girigoswami, A., Sakthi, D. R., Harini, K., Agraharam, G., Deepika, B., Pallavi, P., & Girigoswami, K. (2023). Combinatorial effect of doxorubicin entrapped in alginate-chitosan hybrid polymer and cerium oxide nanocomposites on skin cancer management in mice. Journal of Pharmaceutical Sciences, 112, 2891\u20132900.","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"5112_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114135","volume":"158","author":"C Liu","year":"2023","unstructured":"Liu, C., Wu, K., Li, J., Mu, X., Gao, H., & Xu, X. (2023). Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects. Biomedicine & Pharmacotherapy, 158, 114135.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"5112_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M., Marin, J., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., Calvisi, D. F., Perugorria, M. J., Fabris, L., Boulter, L., Macias, R., Gaudio, E., Alvaro, D., Gradilone, S. A., Strazzabosco, M., \u2026 Gores, G. J. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nature Reviews. Gastroenterology & Hepatology, 17, 557\u2013588.","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"5112_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., Galle, P. R., Rimassa, L., Heurgue, A., Tam, V. C., Van Dao, T., Thungappa, S. C., Breder, V., Ostapenko, Y., Reig, M., \u2026 Abou-Alfa, G. K. (2024). Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Annals of Oncology, 35, 448\u2013457.","journal-title":"Annals of Oncology"},{"key":"5112_CR14","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y., Khodadadi, F., Kashani, S., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O\u2019Byrne, K., & Kulasinghe, A. (2022). Immune checkpoint inhibitors in cancer therapy. Current Oncology, 29, 3044\u20133060.","journal-title":"Current Oncology"},{"key":"5112_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"D Oh","year":"2022","unstructured":"Oh, D., Lee, K., Lee, D., Yoon, J., Kim, T., Bang, J., Nam, A., Oh, K., Kim, J., Lee, Y., Guthrie, V., McCoon, P., Li, W., Wu, S., Zhang, Q., Rebelatto, M. C., & Kim, J. W. (2022). Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study. The lancet. Gastroenterology & hepatology., 7, 522.","journal-title":"The lancet. Gastroenterology & hepatology."},{"key":"5112_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris","year":"2024","unstructured":"Burris, H. A., Okusaka, T., Vogel, A., Lee, M. A., Takahashi, H., Breder, V., Blanc, J., Li, J., Bachini, M., \u017botkiewicz, M., Abraham, J., Patel, N., Wang, J., Ali, M., Rokutanda, N., Cohen, G., & Oh, D. (2024). Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet oncology., 25, 626\u2013635.","journal-title":"The lancet oncology."},{"key":"5112_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D. Y., Banerjee, S., Gonzalez-Martin, A., Jung, K. H., Lugowska, I., Manso, L., Manzano, A., Melichar, B., Siena, S., Stroyakovskiy, D., Fielding, A., Ma, Y., Puvvada, S., Shire, N., & Lee, J. Y. (2024). Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. Journal of Clinical Oncology, 42, 47\u201358.","journal-title":"Journal of Clinical Oncology"},{"key":"5112_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10565-019-09496-2","volume":"36","author":"JG Nirmala","year":"2020","unstructured":"Nirmala, J. G., & Lopus, M. (2020). Cell death mechanisms in eukaryotes. Cell Biology and Toxicology, 36, 145\u2013164.","journal-title":"Cell Biology and Toxicology"},{"key":"5112_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot, D., Latz, E., & Franklin, B. S. (2021). Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cellular & Molecular Immunology, 18, 1106\u20131121.","journal-title":"Cellular & Molecular Immunology"},{"key":"5112_CR20","doi-asserted-by":"crossref","unstructured":"Girigoswami AGAK. Cell death mechanisms elicited by multifactorial stress inducers- A minireview. Bentham Science. 2023; 4: .","DOI":"10.2174\/0126667975259454230920150008"},{"key":"5112_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","volume":"187","author":"K Newton","year":"2024","unstructured":"Newton, K., Strasser, A., Kayagaki, N., & Dixit, V. M. (2024). Cell death. Cell, 187, 235\u2013256.","journal-title":"Cell"},{"key":"5112_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","volume":"116","author":"NN Danial","year":"2004","unstructured":"Danial, N. N., & Korsmeyer, S. J. (2004). Cell death: Critical control points. Cell, 116, 205\u2013219.","journal-title":"Cell"},{"key":"5112_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1196\/annals.1299.032","volume":"1010","author":"E Szegezdi","year":"2003","unstructured":"Szegezdi, E., Fitzgerald, U., & Samali, A. (2003). Caspase-12 and ER-stress-mediated apoptosis: The story so far. Annals of the New York Academy of Sciences, 1010, 186\u2013194.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"5112_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong, R. S. (2011). Apoptosis in cancer: From pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research, 30, 87.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"5112_CR25","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1172\/JCI26252","volume":"115","author":"IN Lavrik","year":"2005","unstructured":"Lavrik, I. N., Golks, A., & Krammer, P. H. (2005). Caspases: Pharmacological manipulation of cell death. The Journal of Clinical Investigation, 115, 2665\u20132672.","journal-title":"The Journal of Clinical Investigation"},{"key":"5112_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2121-3","volume":"580","author":"CB Medina","year":"2020","unstructured":"Medina, C. B., Mehrotra, P., Arandjelovic, S., Perry, J., Guo, Y., Morioka, S., Barron, B., Walk, S. F., Ghesquiere, B., Krupnick, A. S., Lorenz, U., & Ravichandran, K. S. (2020). Metabolites released from apoptotic cells act as tissue messengers. Nature, 580, 130\u2013135.","journal-title":"Nature"},{"key":"5112_CR27","doi-asserted-by":"publisher","first-page":"2138971866","DOI":"10.1177\/0963689720979162","volume":"30","author":"C Liu","year":"2021","unstructured":"Liu, C., Xuan, L., Li, K., Feng, Z., Lv, C., Li, X., Ji, X., Wan, R., & Shen, J. (2021). Shikonin inhibits cholangiocarcinoma cell line QBC939 by regulating apoptosis, proliferation, and invasion. Cell Transplantation, 30, 2138971866.","journal-title":"Cell Transplantation"},{"key":"5112_CR28","doi-asserted-by":"publisher","first-page":"1098915","DOI":"10.3389\/fphar.2023.1098915","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang, C., Yang, H. Y., Gao, L., Bai, M. Z., Fu, W. K., Huang, C. F., Mi, N. N., Ma, H. D., Lu, Y. W., Jiang, N. Z., Tian, L., Cai, T., Lin, Y. Y., Zheng, X. X., Gao, K., Chen, J. J., & Meng, W. B. (2023). Lanatoside C decelerates proliferation and induces apoptosis through inhibition of STAT3 and ROS-mediated mitochondrial membrane potential transformation in cholangiocarcinoma. Frontiers in Pharmacology, 14, 1098915.","journal-title":"Frontiers in Pharmacology"},{"key":"5112_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.720370","volume":"8","author":"J Chen","year":"2021","unstructured":"Chen, J., Pan, Q., Bai, Y., Chen, X., & Zhou, Y. (2021). Hydroxychloroquine induces apoptosis in cholangiocarcinoma via reactive oxygen species accumulation induced by autophagy inhibition. Frontiers in Molecular Biosciences, 8, 720370.","journal-title":"Frontiers in Molecular Biosciences"},{"key":"5112_CR30","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/1535-7163.MCT-23-0126","volume":"22","author":"L Mutlu","year":"2023","unstructured":"Mutlu, L., Manavella, D. D., Bellone, S., McNamara, B., Harold, J. A., Mauricio, D., Siegel, E. R., Buza, N., Hui, P., Hartwich, T. M. P., Yang-Hartwich, Y., Demirkiran, C., Verzosa, M. S. Z., Altwerger, G., Ratner, E. S., Huang, G. S., Clark, M., Andikyan, V., Azodi, M., \u2026 Santin, A. D. (2023). In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma. Molecular Cancer Therapeutics, 22, 1404\u20131412.","journal-title":"Molecular Cancer Therapeutics"},{"key":"5112_CR31","doi-asserted-by":"crossref","unstructured":"Qiang N, Wei L, Tao Y, Jin W, Bin Y and DingHua Z. Construction of Durvalumab\/carbon nanotube\/PEI\/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma. Biomed Mater. 2022; 17: .","DOI":"10.1088\/1748-605X\/ac5414"},{"key":"5112_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-017-0424-0","volume":"10","author":"S Ling","year":"2017","unstructured":"Ling, S., Xie, H., Yang, F., Shan, Q., Dai, H., Zhuo, J., Wei, X., Song, P., Zhou, L., Xu, X., & Zheng, S. (2017). Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: Roles of p38 MAPK, ERK3, and mTORC1. Journal of Hematology & Oncology, 10, 59.","journal-title":"Journal of Hematology & Oncology"},{"key":"5112_CR33","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1245\/s10434-019-07649-5","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y., Luo, J., Dong, X., Yang, F., Zhang, M., Zhao, J., Wang, Q., Zhou, F., Sun, J., & Yang, X. (2019). Establishment and characterization of two novel cholangiocarcinoma cell lines. Annals of Surgical Oncology, 26, 4134\u20134147.","journal-title":"Annals of Surgical Oncology"},{"key":"5112_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12967-020-02498-3","volume":"18","author":"J Byrling","year":"2020","unstructured":"Byrling, J., Kristl, T., Hu, D., Pla, I., Sanchez, A., Sasor, A., Andersson, R., Marko-Varga, G., & Andersson, B. (2020). Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker. Journal of Translational Medicine, 18, 343.","journal-title":"Journal of Translational Medicine"},{"key":"5112_CR35","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3390\/molecules27072293","volume":"27","author":"M Huo","year":"2022","unstructured":"Huo, M., Xia, A., Cheng, W., Zhou, M., Wang, J., Shi, T., Cai, C., Jin, W., Zhou, M., Liao, Y., & Liao, Z. (2022). Rutin promotes pancreatic cancer cell apoptosis by upregulating miRNA-877-3p expression. Molecules (Basel, Switzerland)., 27, 2293.","journal-title":"Molecules (Basel, Switzerland)."},{"key":"5112_CR36","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/ijms24021316","volume":"24","author":"M Gallorini","year":"2023","unstructured":"Gallorini, M., Di Valerio, V., Bruno, I., Carradori, S., Amoroso, R., Cataldi, A., & Ammazzalorso, A. (2023). Phenylsulfonimide PPAR\u03b1 antagonists enhance Nrf2 activation and promote oxidative stress-induced apoptosis\/pyroptosis in MCF7 breast cancer cells. International journal of molecular sciences., 24, 1316.","journal-title":"International journal of molecular sciences."},{"key":"5112_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.semcancer.2019.07.013","volume":"66","author":"L Emdad","year":"2020","unstructured":"Emdad, L., Bhoopathi, P., Talukdar, S., Pradhan, A. K., Sarkar, D., Wang, X., Das, S. K., & Fisher, P. B. (2020). Recent insights into apoptosis and toxic autophagy: The roles of MDA-7\/IL-24, a multidimensional anti-cancer therapeutic. Seminars in Cancer Biology, 66, 140\u2013154.","journal-title":"Seminars in Cancer Biology"},{"key":"5112_CR38","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., \u2026 Ozguroglu, M. (2017). Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. New England Journal of Medicine, 377, 1919\u20131929.","journal-title":"New England Journal of Medicine"},{"key":"5112_CR39","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/JCO.2020.38.15_suppl.4520","volume":"38","author":"D Oh","year":"2020","unstructured":"Oh, D., Lee, K., Lee, D., Kim, T. Y., Bang, J., Nam, A., Lee, Y., Zhang, Q., Rebelatto, M., Li, W., & Kim, J. W. (2020). Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \u00b1 tremelimumab (T) and gemcitabine\/cisplatin (GemCis) in chemo-na\u00efve advanced biliary tract cancer (aBTC). Journal of Clinical Oncology, 38, 4520.","journal-title":"Journal of Clinical Oncology"},{"key":"5112_CR40","doi-asserted-by":"publisher","first-page":"1397827","DOI":"10.3389\/fimmu.2024.1397827","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao, R., Zhou, J., Miao, Z., Xiong, X., Wei, W., Li, S., & Guo, R. (2024). Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. Frontiers in Immunology, 15, 1397827.","journal-title":"Frontiers in Immunology"},{"key":"5112_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","volume":"29","author":"S Kabraji","year":"2023","unstructured":"Kabraji, S., Ni, J., Sammons, S., Li, T., Van Swearingen, A., Wang, Y., Pereslete, A., Hsu, L., DiPiro, P. J., Lascola, C., Moore, H., Hughes, M., Raghavendra, A. S., Gule-Monroe, M., Murthy, R. K., Winer, E. P., Anders, C. K., Zhao, J. J., & Lin, N. U. (2023). Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clinical Cancer Research, 29, 174\u2013182.","journal-title":"Clinical Cancer Research"},{"key":"5112_CR42","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S. W., Planchard, D., Ahn, M. J., Smit, E. F., de Langen, A. J., Perol, M., Pons-Tostivint, E., Novello, S., Hayashi, H., Shimizu, J., Kim, D. W., Kuo, C. H., Yang, J. C., Pereira, K., Cheng, F. C., \u2026 Janne, P. A. (2023). Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. Journal of Clinical Oncology, 41, 4852\u20134863.","journal-title":"Journal of Clinical Oncology"},{"key":"5112_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642547","volume":"11","author":"B Wang","year":"2021","unstructured":"Wang, B., Guo, H., Yu, H., Chen, Y., Xu, H., & Zhao, G. (2021). The role of the transcription factor EGR1 in cancer. Frontiers in Oncology, 11, 642547.","journal-title":"Frontiers in Oncology"},{"key":"5112_CR44","doi-asserted-by":"crossref","unstructured":"Yen JH, Lin CY, Chuang CH, Chin HK, Wu MJ and Chen PY. Nobiletin promotes megakaryocytic differentiation through the MAPK\/ERK-dependent EGR1 expression and exerts anti-leukemic effects in human chronic myeloid leukemia (CML) K562 cells. Cells. 2020; 9: .","DOI":"10.3390\/cells9040877"},{"key":"5112_CR45","doi-asserted-by":"crossref","unstructured":"XIAO D, CHINNAPPAN D, PESTELL R, ALBANESE C and WEBER HC. Bombesin regulates cyclin D1 expression through the early growth response protein egr-1 in prostate cancer cells. Cancer research (Chicago, Ill.). 2005; 65: 9934\u20139942.","DOI":"10.1158\/0008-5472.CAN-05-1830"},{"key":"5112_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3892\/ol.2016.5488","volume":"13","author":"S Leelawat","year":"2017","unstructured":"Leelawat, S., & Leelawat, K. (2017). Molecular mechanisms of cholangiocarcinoma cell inhibition by medicinal plants. Oncology Letters, 13, 961\u2013966.","journal-title":"Oncology Letters"},{"key":"5112_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-020-01016-8","volume":"14","author":"Y Ding","year":"2021","unstructured":"Ding, Y., Chen, X., Liu, C., Ge, W., Wang, Q., Hao, X., Wang, M., Chen, Y., & Zhang, Q. (2021). Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells. Journal of Hematology & Oncology, 14, 19.","journal-title":"Journal of Hematology & Oncology"},{"key":"5112_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41420-021-00805-5","volume":"8","author":"L Zhou","year":"2022","unstructured":"Zhou, L., Li, J., Liu, X., Tang, Y., Li, T., Deng, H., Chen, J., Yin, X., Hu, K., & Ouyang, W. (2022). Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a\/EGR1 axis. Cell death discovery., 8, 31.","journal-title":"Cell death discovery."},{"key":"5112_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcp.2016.01.011","volume":"104","author":"CN Koyani","year":"2016","unstructured":"Koyani, C. N., Kitz, K., Rossmann, C., Bernhart, E., Huber, E., Trummer, C., Windischhofer, W., Sattler, W., & Malle, E. (2016). Activation of the MAPK\/Akt\/Nrf2-Egr1\/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death. Biochemical Pharmacology, 104, 29\u201341.","journal-title":"Biochemical Pharmacology"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-024-05112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-024-05112-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-024-05112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T01:47:55Z","timestamp":1743558475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-024-05112-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["5112"],"URL":"https:\/\/doi.org\/10.1007\/s12010-024-05112-0","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"type":"print","value":"0273-2289"},{"type":"electronic","value":"1559-0291"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"19 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Liaoning Cancer Hospital and Institute (approval number: 20230450). This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}